Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices